BOSTON--(BUSINESS WIRE)--FDNA and Vanderbilt University Medical Center announce integration of FDNA’s Face2Gene suite of applications into the Vanderbilt Center for Undiagnosed Diseases workflow to evaluate difficult-to-diagnose patients in their role as part of the National Institutes of Health (NIH) Undiagnosed Disease Network (UDN).
Participating institutions in the UDN use the most advanced approaches in genomics and research to search for answers for patients who have been unable to find a diagnosis. The UDN is made up of seven top-ranked institutions in the United States. Vanderbilt University Medical Center is the first of many sites that have approached FDNA to use Face2Gene for UDN cases.
“FDNA’s mission aligns perfectly with Vanderbilt and the UDN,” said Dekel Gelbman, CEO, FDNA. “We are all working to find answers for patients who have waited far too long, and with this collaboration, we believe we are one step closer.”
Used by more than 70% of clinical geneticists globally, Face2Gene is a platform that uses next-generation phenotyping (NGP) technologies to analyze a patient’s facial and clinical features to highlight syndromes and genetics that may have otherwise been missed during patient evaluations.
About Vanderbilt University Center for UDN
The Vanderbilt Center for Undiagnosed Diseases brings together clinical and research experts from across Vanderbilt University Medical Center with experts across the world to solve patient's most challenging medical mysteries. Vanderbilt University Medical Center is one of seven medical centers around the country in the Undiagnosed Diseases Network (UDN), a clinical research initiative of the National Institutes of Health.
About FDNA and Face2Gene
FDNA is the developer of Face2Gene, a clinical suite of phenotyping applications that facilitates comprehensive and precise genetic evaluations. Face2Gene uses facial analysis, deep learning and artificial intelligence to transform big data into actionable genomic insights to improve and accelerate diagnostics and therapeutics. With the world’s largest network of clinicians, labs and researchers creating one of the fastest growing and most comprehensive genomic databases, FDNA is changing the lives of patients with diseases with genetic causes. For more information, visit www.FDNA.com. Face2Gene is a registered trademark of FDNA INC.